Document Detail

Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment.
Jump to Full Text
MedLine Citation:
PMID:  21941412     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An essential cytokine system for the osteoclast biology in multiple myeloma (MM) consists of the receptor of activator of NF-κB ligand (RANKL), its receptor (RANK), and the soluble decoy receptor, osteoprotegerin (OPG). Myeloma cells cause imbalance in OPG/RANKL interactions. We measured serum levels of OPG, soluble (s) RANKL, sRANKL/OPG ratio, markers of disease activity [LDH, CRP, interleukin-6 (IL-6), β2-microglobulin (B2M)], and angiogenic factors [hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF)], in 54 newly diagnosed MM patients and in 25 of them in plateau phase. All the above values were higher in MM patients compared to controls and decreased in plateau phase. sRANKL and RANKL/OPG were higher with advancing disease stage and skeletal grade. Significant correlations were found among RANKL and RANKL/OPG with HGF, LDH, VEGF, IL-6, and B2M. In conclusion, RANKL and OPG play significant roles in MM pathophysiology, as regulators of bone turnover and mediators of angiogenesis.
Authors:
K Sfiridaki; C A Pappa; G Tsirakis; P Kanellou; M Kaparou; M Stratinaki; G Sakellaris; G Kontakis; M G Alexandrakis
Publication Detail:
Type:  Journal Article     Date:  2011-09-18
Journal Detail:
Title:  Mediators of inflammation     Volume:  2011     ISSN:  1466-1861     ISO Abbreviation:  Mediators Inflamm.     Publication Date:  2011  
Date Detail:
Created Date:  2011-09-23     Completed Date:  2012-01-23     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  9209001     Medline TA:  Mediators Inflamm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  867576     Citation Subset:  IM    
Affiliation:
Blood Bank, Venizelion General Hospital of Heraklion, 71409 Crete, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Cytokines / blood*
Female
Humans
Male
Middle Aged
Multiple Myeloma / blood*,  pathology,  physiopathology
Neovascularization, Pathologic*
Osteoprotegerin / blood*
RANK Ligand / blood*
Chemical
Reg. No./Substance:
0/Cytokines; 0/Osteoprotegerin; 0/RANK Ligand
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Mediators Inflamm
Journal ID (publisher-id): MI
ISSN: 0962-9351
ISSN: 1466-1861
Publisher: Hindawi Publishing Corporation
Article Information
Download PDF
Copyright © 2011 K. Sfiridaki et al.
open-access:
Received Day: 12 Month: 5 Year: 2011
Revision Received Day: 21 Month: 7 Year: 2011
Accepted Day: 21 Month: 7 Year: 2011
Print publication date: Year: 2011
Electronic publication date: Day: 18 Month: 9 Year: 2011
Volume: 2011E-location ID: 867576
ID: 3175728
PubMed Id: 21941412
DOI: 10.1155/2011/867576

Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment
K. Sfiridaki1
C. A. Pappa1
G. Tsirakis2
P. Kanellou2
M. Kaparou2
M. Stratinaki1
G. Sakellaris3
G. Kontakis3
M. G. Alexandrakis2*
1Blood Bank, Venizelion General Hospital of Heraklion, 71409 Crete, Greece
2Department of Haematology, University Hospital of Heraklion, 70013 Crete, Greece
3Department of Surgery, University Hospital of Heraklion, 70013 Crete, Greece
Correspondence: *M. G. Alexandrakis: alexandm@med.uoc.gr
[other] Academic Editor: Fulvio D'Acquisto

1. Introduction

Multiple myeloma is a malignant plasma cell proliferation localized in the bone marrow with debilitating skeletal involvement. Much of its morbidity is accounted to bone pain and pathologic fractures due to the imbalance between bone formation and breakdown in favor of the latter [14].

These complications are due to an excessive osteoclast activity, which are stimulated by osteoclast-activating factors, including Tumor Necrosis Factor (TNF), Interleukin-1 (IL-1), Interleukin-6 (IL-6), the chemokines Macrophage Inflammatory Protein-1a (MIP-1a), Macrophage Inflammatory Protein-1β (MIP-1β), and Stroma cell-Derived Factor-1a (SDF-1a) [2, 5, 6].

However, an essential cytokine system for the osteoclast biology has been identified and consists of the receptor of activator of NF-κB ligand (RANKL), its receptor RANK, and the soluble decoy receptor, osteoprotegerin (OPG) [79]. The RANKL has been identified and associated with the enhancement in osteoblast-induced bone resorption, while OPG blocks RANKL and inhibits bone resorption [8, 10]. Myeloma plasma cells have been found to induce an imbalance in the OPG/RANKL interactions, increasing RANKL expression and decreasing OPG availability in the bone microenvironment, inducing an enhancement of the osteoclastic activation and increased bone resorption [8, 11].

RANKL stimulates osteoclast differentiation and activity and also inhibits osteoclast apoptosis. RANKL is mainly produced by osteoblastic lineage cells, immune cells, and some malignant cells [12].

Osteoprotegerin is a Tumor Necrosis Factor Receptor-2 (TNFR-2) and CD40 homologous protein, which lacks a transmembrane domain and is secreted into the extracellular space as a homodimeric glycoprotein [13, 14]. OPG was found in serum of peripheral blood in various forms, in complexes with soluble RANKL and a free non-bound portion. The heterogeneity of these circulating forms may account for the discrepancies for absolute values reported in the literature [11]. Based on the heterogeneity of circulating forms and other technical aspects, the protein used as standard and the suitable calibrator diluent could account for discrepant results that have been obtained by different groups in the literature [11, 15].

Bone marrow angiogenesis is an important additional process contributing to disease progress [16, 17]. Various angiogenic cytokines, such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) increase myeloma cell proliferation and accelerate bone resorption [16, 18].

The purpose of this study was to evaluate serum levels of OPG, soluble RANKL (sRANKL), the ratio sRANKL/OPG, VEGF, HGF, and known factors of disease activity at diagnosis and in plateau phase and to estimate the effect of treatment on their circulating levels in patients with MM.


2. Patients and Methods
2.1. Patients

Fifty-four MM patients (28 males, 26 females) were included in this study. The median age was 64 years (range 51–87 years). Patients were diagnosed and categorized according to the Durie-Salmon classification system [19]. Sixteen patients were classified as stage I, 19 as stage II, and 19 as stage III. The types of monoclonal protein were 21 IgGκ, 8 IgGλ, 7 IgAκ, 11 IgAλ, and light chain disease for 7 patients. Bone involvement was graded according to standard X-ray evaluation into two scores: low score in 26 patients overall, including patients with no lesions, one bone involved, or diffuse osteoporosis; and high score in 28 patients overall, including patients with lesions in more than one bone or presence of bone fracture. None of the patients had received any treatment with corticosteroids or biphosphonates before entering the study. Eighteen patients had normal radiographic findings of the skeleton, the rest displayed osteolytic lesions. Twenty-five of the patients achieved complete remission or very good partial remission after treatment with PAD (bortezomib, doxorubicin, dexamethasone) regimen followed by autologous stem cell transplantation and considered to be in plateau phase. Twenty age- and sex-matched healthy subjects (12 male and 8 female, mean age 63.6 ± 10.8 years) were recruited as controls among blood donors (up to 60 years of age) and people following a physical training program (over 60 years of age). Informed consent for the study was obtained from all subjects. The study was conducted with the understanding and the consent of the human subject. The responsible Ethical Committee has approved the experiments.

2.2. Methods

Serum samples from patients were collected before starting treatment at diagnosis and during stable disease. Sera collected from patients and controls were aliquoted into separate vials and stored at −7°C. All assays were performed at the end of the study, in order to avoid interassay variability.

The detection of VEGF, HGF, IL-6, sRANKL, and OPG in the serum was performed by a solid-phase sandwich ELISA, using monoclonal antibodies against VEGF, HGF, and IL-6 (Quantikine, R&D systems Inc. Mineapolis, MN, USA) and sRANKL and OPG antibodies (Bio Vendor-Laboratorni Medicina as Brno, Czech Republic). Measurements were performed according to the manufacturers' instructions. Briefly, antibodies specific for each growth factor (VEGF, HGF, IL-6, sRANKL, and OPG) were coated in microtitter wells. After the addition of controls and samples and a first incubation and washing, an enzyme-linked polyclonal antibody specific for each growth factor was added to each well. After an incubation time and the last washing step, the remaining conjugate is allowed to react with the substrate. During the next step, the reaction was stopped by addition of specific solution, and the absorbance of the resulting color is measured at 450 nm. Biochemical markers that were studied were C-reactive protein (CRP), β2-microglobulin (B2M), and serum lactate dehydrogenase (LDH). The above mentioned parameters were evaluated using conventional techniques. CRP was determined by nephelometry, B2M by radioimmunoassay, and serum LDH was determined using standard laboratory methods. Radiographic examination including skull, pelvis, long bones and cervical, thoracic, and lumbar spine was carried out in all patients as a routine staging procedure. Bone disease was graded according to Durie and Salmon criteria [19].

2.3. Statistical Analysis

Data are presented as means ± SD. The Mann-Whitney U-test was applied to evaluate any difference in serum cytokine levels in patients and healthy individuals. Nonparametric tests were also used (Mann-Whitney and Wilcoxon for independent and paired two samples statistics). The investigation of potential correlations among variables was carried out with the Spearman's rho correlation coefficient. P  values < 0.05 were considered to be statistically significant.


3. Results

The laboratory findings studied in multiple myeloma patients and in healthy controls are shown in Table 1. Serum mean concentration of OPG was 12.5 ± 11.5 (0.7–60.2) pmol/L in multiple myeloma patients and 6.4 ± 5.3 (0.7–17.4) pmol/L in healthy subjects (P < 0.03) (by Mann-Whitney test) (Figure 1). The mean concentrations of OPG in stages I and II of the disease were higher than in stage III, without statistical significance. Our results also showed that OPG serum levels were significantly decreasing after treatment (11.5 ± 10.9 versus 13.3 ± 14.0 pmol/L, P < 0.03, Wilcoxon test) (Figure 2). Serum concentrations of sRANKL were also increased in patients compared to controls, whereas sRANKL/OPG ratio did not show significant difference. On the other hand, both serum levels of sRANKL and sRANKL/OPG ratio were increased with disease progression and decreased after effective treatment.

In healthy individuals, mean serum levels for HGF were 465.3 ± 163.4 (311.9–898.7) pg/mL, for VEGF 90.2 ± 14.4 (68.7–111.6) pg/mL and for IL-6 0.8 ± 0.5 (0.4–2.0) pg/mL. Pretreatment VEGF, HGF, and IL-6 serum levels were increased in MM patients in comparison with healthy individuals (P < 0.001, in all cases). Significant differences were found for HGF, VEGF, and IL-6 between the stages of the disease (Table 2).

3.1. Relationship between Biochemical Markers, Cytokines, and Skeletal Involvement

There was a positive correlation between increasing bone lesion score and serum median concentrations of sRANKL (P < 0.001), sRANKL/OPG ratio (P < 0.001), VEGF (P < 0.001) (Figure 3), HGF (P < 0.004), IL-6 (P < 0.001), LDH (P < 0.05), and B2M (P < 0.04), while OPG levels according to bone disease were higher in low score (grade 0-1) in comparison to high score (grade 2-3) but without statistical significance (Table 3).

3.2. Correlation between Measured Parameters

Positive correlations were found between sRANKL with HGF, VEGF, LDH, VEGF, B2M, and IL-6, whereas more powerful correlations were found between sRANKL/OPG ratio with OPG and the above parameters (Table 4). Serum HGF correlated positively with LDH (r = 0.38, P < 0.002), VEGF (r = 0.59, P < 0.0001), B2M (r = 49, P < 0.0001), CRP (r = 420, P < 0.001), and IL-6 (r = 61, P < 0.0001).

No correlation between the angiogenic cytokines VEGF, HGF and IL-6, and the serum OPG levels was found. Similarly, no correlation between the parameters of disease activity CRP, B2M, and LDH serum levels with OPG levels was found.

Finally, statistically significant differences were observed in the serum levels, before and after treatment, of OPG, HGF, LDH, VEGF, and IL-6 (Table 5).


4. Discussion

Angiogenesis is a crucial factor for the growth and progression of multiple myeloma [16, 20, 21]. Various angiogenic cytokines have been characterized as potent mitogens with angiogenic activity [22, 23]. Neovascularization and bone marrow microenvironment capacity to support the proliferation of tumor cells as well as the interactions between plasma cells and osteoclasts are important processes involved in MM pathogenesis [24]. VEGF is a potent mitogen for endothelial cells and is regarded as one of the most important molecules for its role in the vascularization of bone tissues [25]. Another factor with potent angiogenic activity is the HGF. HGF and its receptor c-met are expressed simultaneously in myeloma cells [26]. In MM patients elevated levels of HGF in the serum have been found to be associated with a poor prognosis [16, 27]. HGF appears to play a significant role in tumor angiogenesis by stimulating endothelial cell migration, proliferation, and capillary tube formation [28].

Three potential novel regulators of endothelial cell function and angiogenesis have been described. These are OPG and its ligands, RANKL and TNF-Related Apoptosis Inducing Ligand (TRAIL) [29]. In a recent study, it has been found that OPG is expressed in neovessels associated with malignant tumors and in angiogenic microvessels associated with inflammatory osteodestructive diseases [2931]. Moreover, OPG with other angiogenic factors such as VEGF was found to have an additive effect on endothelial cell tube formation [32]. Since OPG is a decoy receptor for the above TNF family ligands, it seems that it exerts its angiogenic effect through inhibition of one or both of these molecules. In fact, using excess molar amounts of either TRAIL or RANKL, the angiogenic activity of OPG can be blocked. However, only RANKL was found to be an angiogenesis inhibitor by its own. So, RANKL reduces endothelial cell proliferation and induces their apoptosis, in vitro [13], whereas its role in regulating cell proliferation and survival differs between cell types, mainly due to the complex network of signals initiated by its interaction with RANK. IL-6 has been proposed as the major myeloma plasma cell growth factor. Furthermore, IL-6 has been shown to be a potent bone resorbing factor and may be involved in the production of bone lesions in MM patients [33].

In the present study, our results showed increasing serum levels of OPG in MM patients compared to the control group (P < 0.01). OPG serum levels show a tendency to decrease in advanced clinical stage and in patients with high score of bone disease (the lowest OPG serum levels were observed in patients with grade 3 bone disease). Higher levels of OPG were found in early clinical stages and in patients with minimal bone lesions (grade I). Probably, in patients without bone involvement, activity of ostepblasts is still coupled to the osteoclastic function. Osteoblast function decreases as the disease evolves and is the result of the suppressive effects of MM cells [34]. Our results are in agreement with others [11, 34] that OPG serum levels are elevated even in myeloma patients without bone lesions. In later stages of the disease, bone formation and osteoblast function are impaired which gives an explanation to the reduced OPG levels in patients with increased bone destruction [11, 34, 35]. No statistically significant difference was observed between OPG serum levels in pre and posttreatment MM patients and no significant correlation was observed with other parameters of disease activity at diagnosis and after treatment such as LDH, CRP, B2M, and IL-6. Recently, it has been reported that OPG blocks bone cancer-induced skeletal destruction after administration experimentally in mice with sarcoma-induced osteolysis [36]. Probably as reported recently the decreased level of OPG in myeloma bone disease gives a rationale for OPG as a new treatment for MM bone disease [37].

Furthermore, in our study we have shown that serum sRANKL levels were increased in MM patients compared to controls. This agrees with most other studies [34, 38]. RANKL and RANKL/OPG ratios, significantly increase with advancing disease stage and in patients with severe bone lesions. Furthermore, RANKL and RANKL/OPG ratios have positive correlations with clinical stage, grade of bone disease, angiogenic cytokines (HGF and VEGF), and factors of disease activity such as IL-6, B2M, and LDH. The only correlation of OPG serum levels was with RANKL/OPG ratio.

To our best knowledge, no study until now has assessed a correlation between OPG, RANKL serum levels, their ratio RANKL/OPG and angiogenic cytokines such as HGF, VEGF, and IL-6 serum levels. In conclusion, OPG and RANKL are cytokines with a significant role in the pathophysiology of MM as regulators of bone turnover but also as significant mediators of angiogenesis. The exact role of OPG and RANKL in the mechanisms of angiogenesis and osteo-destructive disease in MM remains to be clarified.


References
1. Mundy GR. Myeloma bone diseaseEuropean Journal of CancerYear: 19983422462519741328
2. Pearse RN. Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodelingClinical Cancer ResearchYear: 200612206274s6278s17062713
3. Alexandrakis MG,Passam FH,Malliaraki N,Katachanakis C,Kyriakou DS,Margioris AN. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patientsClinica Chimica ActaYear: 20023251-25157
4. Yaccoby S,Pearse RN,Johnson CL,Barlogie B,Choi Y,Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activityBritish Journal of HaematologyYear: 2002116227829011841428
5. Roodman GD. Mechanisms of bone metastasisThe New England Journal of MedicineYear: 2004350161655169815084698
6. Heider U,Hofbauer LC,Zavrski I,Kaiser M,Jakob C,Sezer O. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone diseaseBiochemical and Biophysical Research CommunicationsYear: 2005338268769316216218
7. Hsu H,Lacey DL,Dunstan CR,et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligandProceedings of the National Academy of Sciences of the United States of AmericaYear: 19999673540354510097072
8. Khosla S. Minireview: the OPG/RANKL/RANK systemEndocrinologyYear: 2001142125050505511713196
9. Standal T,Seidel C,Hjertner Ø,et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cellsBloodYear: 200210083002300712351414
10. Lacey DL,Timms E,Tan HL,et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationCellYear: 19989321651769568710
11. Corso A,Dovio A,Rusconi C,et al. Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controlsLeukemiaYear: 20041891555155715241438
12. Sezer O,Heider U,Zavrski I,Kühne CA,Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone diseaseBloodYear: 200310162094209812424190
13. Simonet WS,Lacey DL,Dunstan CR,et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone densityCellYear: 19978923093199108485
14. McGonigle JS,Giachelli CM,Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell functionAngiogenesisYear: 2009121354619105036
15. Lipton A,Ali SM,Leitzel K,et al. Serum osteoprotegerin levels in healthy controls and cancer patientsClinical Cancer ResearchYear: 2002872306231012114435
16. Alexandrakis MG,Passam FJ,Ganotakis E,et al. Bone marrow microvascular density and angiogenic growth factors in multiple myelomaClinical Chemistry and Laboratory MedicineYear: 200442101122112615552270
17. Vacca A,Ribatti D,Presta M,et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myelomaBloodYear: 19999393064307310216103
18. Alexandrakis MG,Sfiridaki A,Miyakis S,et al. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myelomaClinica Chimica ActaYear: 20073791-23135
19. Durie BGM,Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancerYear: 19753638428541182674
20. Rajkumar SV,Leong T,Roche PC,et al. Prognostic value of bone marrow angiogenesis in multiple myelomaClinical Cancer ResearchYear: 2000683111311610955791
21. Folkman J,Shing Y. AngiogenesisThe Journal of Biological ChemistryYear: 19922671610931109341375931
22. Alexandrakis MG,Passam FH,Boula A,et al. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myelomaAnnals of HematologyYear: 2003821192312574959
23. Sezer O,Jakob C,Eucker J,et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myelomaEuropean Journal of HaematologyYear: 2001662838811168514
24. Yaccoby S,Pearse RN,Johnson CL,Barlogie B,Choi Y,Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activityBritish Journal of HaematologyYear: 2002116227829011841428
25. Carlevaro MF,Cermelli S,Cancedda R,Cancedda FD. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formationJournal of Cell ScienceYear: 20001131596910591625
26. Børset M,Lien E,Espevik T,Helseth E,Waage A,Sundan A. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell linesThe Journal of Biological ChemistryYear: 19962714024655246618798732
27. Seidel C,Børset M,Turesson I,Abildgaard N,Sundan A,Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myelomaBloodYear: 19989138068129446640
28. Grant DS,Kleinman HK,Goldberg ID,et al. Scatter factor induces blood vessel formation in vivoProceedings of the National Academy of Sciences of the United States of AmericaYear: 1993905193719417680481
29. Pritzker LB,Scatena M,Giachelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survivalMolecular Biology of the CellYear: 20041562834284115064358
30. Cross SS,Yang Z,Brown NJ,et al. Osteoprotegerin (OPG)—A potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?International Journal of CancerYear: 2006118819011908
31. Haynes DR,Barg E,Crotti TN,et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controlsRheumatologyYear: 200342112313412509625
32. Reid PE,Brown NJ,Holen I. Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contactMolecular CancerYear: 20098, article 49
33. Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implicationsCancerYear: 200397102440245212733143
34. Goranova-Marinova V,Goranov S,Pavlov P,Tzvetkova T. Serum levels of OPG, RANKL and RANKL/OPG ratios in newly-diagnosed patients with multiple myeloma. Clinical correlationsHaematologicaYear: 20079271000100117606458
35. Bataille R,Chappard D,Marcelli C,et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone diseaseJournal of Clinical OncologyYear: 1989712190919142585025
36. Honore P,Luger NM,Sabino MAC,et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cordNature MedicineYear: 200065521528
37. Seidel C,Hjertner O,Abildgaard N,et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone diseaseBloodYear: 20019872269227111568016
38. Terpos E,Szydlo R,Apperley JF,et al. Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic indexBloodYear: 200310231064106912689925

Article Categories:
  • Clinical Study


Previous Document:  DHA supplementation during pregnancy and lactation affects infants' cellular but not humoral immune ...
Next Document:  Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.